Tackling Glaucoma from within the Brain: An Unfortunate Interplay of BDNF and TrkB by Dekeyster, Eline et al.
RESEARCH ARTICLE
Tackling Glaucoma from within the Brain: An
Unfortunate Interplay of BDNF and TrkB
Eline Dekeyster1, Emiel Geeraerts1, Tom Buyens1, Chris Van den Haute2,3,
Veerle Baekelandt2, Lies De Groef1, Manuel Salinas-Navarro1, Lieve Moons1*
1 Neural Circuit Development and Regeneration Research Group, Department of Biology, KU Leuven,
Leuven, Belgium, 2 Neurobiology and Gene Therapy Research Group, Department of Neurosciences, KU
Leuven, Leuven, Belgium, 3 Leuven Viral Vector Core, KU Leuven, Leuven, Belgium
* lieve.moons@bio.kuleuven.be
Abstract
According to the neurotrophin deprivation hypothesis, diminished retrograde delivery of
neurotrophic support during an early stage of glaucoma pathogenesis is one of the main
triggers that induce retinal ganglion cell (RGC) degeneration. Therefore, interfering with
neurotrophic signaling seems an attractive strategy to achieve neuroprotection. Indeed,
exogenous neurotrophin administration to the eye has been shown to reduce loss of RGCs
in animal models of glaucoma; however, the neuroprotective effect was mostly insufficient
for sustained RGC survival. We hypothesized that treatment at the level of neurotrophin-
releasing brain areas might be beneficial, as signaling pathways activated by target-derived
neurotrophins are suggested to differ from pathways that are initiated at the soma mem-
brane. In our study, first, the spatiotemporal course of RGC degeneration was characterized
in mice subjected to optic nerve crush (ONC) or laser induced ocular hypertension (OHT).
Subsequently, the well-known neurotrophin brain-derived neurotrophic factor (BDNF) was
chosen as the lead molecule, and the levels of BDNF and its high-affinity receptor, tropomy-
osin receptor kinase B (TrkB), were examined in the mouse retina and superior colliculus
(SC) upon ONC and OHT. Both models differentially influenced BDNF and TrkB levels.
Next, we aimed for RGC protection through viral vector-mediated upregulation of collicular
BDNF, thought to boost the retrograde neurotrophin delivery. Although the previously
reported temporary neuroprotective effect of intravitreally delivered recombinant BDNF was
confirmed, viral vector-induced BDNF overexpression in the SC did not result in protection
of the RGCs in the glaucoma models used. These findings most likely relate to decreased
neurotrophin responsiveness upon vector-mediated BDNF overexpression. Our results
highlight important insights concerning the complexity of neurotrophic factor treatments that
should surely be considered in future neuroprotective strategies.
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Introduction
Glaucomatous optic neuropathies are characterized by degeneration of retinal ganglion cells
(RGCs) and their axons, resulting in visual field defects[1–3]. The pathophysiological mecha-
nisms underlying glaucomatous RGC death are not completely understood and the sole target
for clinical intervention at present is increased intraocular pressure (IOP) or ocular hyperten-
sion (OHT)[1–3]. Unfortunately, in a significant number of patients, IOP lowering cannot pre-
vent the RGCs from dying[4], encouraging researchers to search for alternative treatment
strategies that aim for neuroprotection of the RGCs.
One of the early events during the pathogenesis of glaucoma is axonal dystrophy within the
optic nerve, perturbing axonal transport of neurotrophins[5, 6]. The neurotrophin deprivation
hypothesis proposes that diminished retrograde transport, resulting in deprivation of brain-
derived neurotrophic support to the RGCs, is one of the triggers that induces glaucomatous ret-
inal cell death[5, 6]. Based on this theory, various experimental strategies have sought to supply
exogenous neurotrophins to curb glaucomatous neurodegeneration[6]. Among the neurotro-
phins linked to glaucoma, brain-derived neurotrophic factor (BDNF) stands out for its vital
role in maintaining RGCs and its potent protective effect in different glaucoma models[6–14].
BDNF is synthesized locally in the retina by RGCs[15] and glia[16, 17], but is also produced in
the RGC projection areas in the brain from where it is taken up by RGC terminals and retro-
gradely transported, as a neurotrophin-receptor complex, via their axons to the cell bodies[5].
BDNF is synthesized as pro-BDNF and can be subsequently cleaved to form mature BDNF
(mBDNF)[18]. The yin and yang model, stating that pro-BDNF merely induces neuronal apo-
ptosis while mBDNF promotes survival[19], has recently been questioned[20, 21]. The neuro-
trophic effects of BDNF are primarily mediated through binding to its high-affinity receptor,
tropomyosin receptor kinase B (TrkB)[13]. TrkB exists in different splice variants, of which
TrkB-full length (TrkB-FL) and TrkB-truncated from 1 (TrkB-T1), lacking the C-terminal
intracellular kinase domain, are the most abundant in the central nervous system[22]. Binding
of BDNF to TrkB-FL induces receptor dimerization and transphosphorylation, leading to acti-
vation of intracellular signaling pathways involved in cell viability[18]. Until now, the exact
role of TrkB-T1 remains less clear[22]. TrkB-T1 was first defined as a dominant-negative
receptor that heterodimerizes with TrkB-FL to indirectly inhibit BDNF survival signaling.
However, more recently, TrkB-T1 has, for example, also been linked to a complex web of intra-
cellular glial signaling pathways, as well as to regulation of extracellular BDNF concentrations
through sequestration [22].
Although local administration of BDNF to the eye has repeatedly been shown to reduce loss
of RGCs in various glaucoma models[6–14], the neuroprotective effect is mostly insufficient to
support sustained RGC survival. Alternative to retinal administration, it might be beneficial to
consider treatment at the level of extraretinal neurotrophin sources in the brain, as target-
derived neurotrophins are likely to induce signaling pathways that differ from local neurotro-
phin signaling[18, 23–25]. Recently, this hypothesis was partially confirmed by combining
intravitreal (ivt) injection with chronic delivery of BDNF into the visual brain centers, which
resulted in prolonged and enhanced RGC survival in cats subjected to optic nerve trauma[7,
26].
The overall objective of this study was to advance the knowledge of the role of neurotrophin
signaling between the eye and the brain in glaucoma pathology. Therefore, two different mouse
models of experimental glaucoma were used: the optic nerve crush (ONC) model, defined by
mechanical trauma to the RGC axons in the optic nerve[27–29], and a laser induced ocular
hypertension (OHT) model, in which IOP is temporary elevated through laser photocoagula-
tion (LP) of the perilimbal and episcleral veins[30, 31]. Although rather acute, both models
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share important features with human glaucoma, where the primary injury to RGCs is also axo-
nal and possibly occurs through OHT-related mechanical forces stressing axons in the optic
nerve head (ONH)[32]. After outlining the RGC degeneration profiles, the temporal patterns
of BDNF and TrkB-FL/TrkB-T1 levels in the retina and superior colliculus (SC), the primary
target for RGC axons in rodents[33], were visualized in both models of experimentally induced
glaucoma. Furthermore, the previously reported neuroprotective effect of ivt recombinant
BDNF administration was re-examined in the ONC model and, in addition, the effect of viral
vector-mediated BDNF upregulation in the SC on RGC survival/death was investigated in both
the ONC and the OHT model.
Materials and Methods
Animals and anesthetics
All experiments were performed on adult C56Bl/6J and CD-1 mice (10–12 weeks old at the
start of the experiment), housed under a 12/12 h light/dark cycle with ad libitum access to food
and water. The experiments were approved by the KU Leuven Animal Ethics Committee and
followed the guidelines of the ARVO statement for the use of animals in ophthalmic and
Vision Res.
Surgical procedures to induce experimental glaucoma and for viral vector or recombinant
BDNF administration were performed under general anaesthesia, induced by intraperitoneal
(i.p.) administration of ketamine (75 mg/kg body weight, Anesketin, Eurovet, Belgium) and
medetomidin (1 mg/kg body weight, Domitor, Janssen Pharmaceutics, Belgium). Additionally,
for glaucoma induction and intravitreal (ivt) injections, a droplet of local analgesic, oxybupro-
caïne hydrochloride (0.4%, Unicaïne, Théa, Belgium) was applied to the eye. For intracollicular
vector injections, the head region was topically analgesized by applying lidocaine hydrochlo-
ride (5%, Xylocaine, AstraZeneca, UK) to the scalp. After any surgical procedure, waking was
encouraged by i.p. administration of atipamezole (1 mg/kg body weight, Antisedan, Pfizer, Bel-
gium). During recovery, tobramycin eye ointment (Tobrex, Alcon, TX, USA) was applied to
the cornea of both eyes to prevent desiccation and mice were placed on a heat pad to maintain
body temperature.
Experimental glaucoma induction
In both models, experimental glaucoma was induced in the left eye (oculus sinister, OS) while
the right eye (oculus dexter, OD) served as an internal control.
Optic nerve crush (ONC) was performed in C57Bl/6J mice as described previously[34].
Briefly, a small temporal incision was made in the conjunctiva and by gently retracting the con-
junctiva, the globe was rotated nasally. Subsequently, blunt dissection was used to create a
space between the temporal lateral rectus muscle and the inferior oblique muscle to expose the
optic nerve. The optic nerve was then crushed 1 mm behind the globe for 5 s using self-closing
cross-action forceps (11262–30, Fine Science Tools, Germany) in order to provide a constant
and consistent pressure of 120 gr/mm2. Before and after the ONC procedure, funduscopy was
performed to ensure a normal retinal perfusion.
Ocular hypertension (OHT) was induced in CD-1 mice through laser photocoagulation
(LP) of the ocular veins as described before[30, 31, 35]. Briefly, after dilating the pupil by a
droplet of tropicamide (1%, Mydriacyl, Alcon, TX, USA), a 532 nm diode laser (Vitra, Quantel
Medical, France) was employed to deliver approximately 70 laser spots (0.5 s exposure time
and 0.3 W power intensity) to the perilimbal and episcleral veins. Before and immediately after
LP, funduscopy was performed to account for ischemic effects. The intraocular pressure (IOP)
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was measured at a defined daily time point in awake animals, before and up to 7 d after LP,
using a calibrated rebound tonometer (Tono-Lab, Icare, Finland).
Intravitreal BDNF administration
Mice received a 2 μl ivt injection of BDNF (Peprotech Laboratories, UK), diluted at 1 mg/ml in
0.01 M phosphate buffered saline (PBS) containing 1% bovine serum albumin (BSA, PanReac
Applichem, Germany) (BSA-PBS). Ivt injections were performed using a glass capillary with a
50–70 μm outer diameter, connected to a Hamilton syringe and a Micro4 Microsyringe con-
troller (World Precision Instruments, FL, USA), at a rate of 500 nl/s. Control groups received
an ivt injection of 2 μl vehicle (BSA-PBS). Two main treatment paradigms were used: (i) a sin-
gle dose immediately after crush with sacrifice at 7 or 14 days post-injury (dpi), and (ii)
repeated ivt injection at 0, 3, and 5 d with sacrifice at 7 dpi, or at 0, 5, and 10 d with sacrifice at
14 d post ONC.
Intracollicular BDNF overexpression induced by viral vector technology
To optimize viral vector transduction in the mouse SC, the tropism and transduction efficiency
of four rAAV serotypes (2/1, 2/7, 2/8, and 2/9) were evaluated. For more information, see sup-
plementary methods described in S1 Text.
In order to enhance BDNF levels in the SC, a murine BDNF-expressing vector was devel-
oped. RNA was isolated from mouse tail tissue using TRIzol reagent (Invitrogen, CA, USA)
and cDNA synthesis was carried out following standard procedures[36]. PCR amplification of
the BDNF cDNA was performed with Phusion high fidelity DNA polymerase (New England
Biolabs, UK) using forward primer 5’-TCTAGAGATGACCATCCTTTTCCTTAC-3’ and
reverse primer 5’-ACTAGTCTATCTTCCCCTTTTAATGGTC-3’. Subsequently, mouse
BDNF cDNA was cloned using the Zero Blunt TOPO PCR Cloning kit (Invitrogen, CA, USA)
and the resulting plasmid was transformed into competent Escherichia coli cells (One shot,
Invitrogen, CA, USA). Plasmids were isolated from positive clones by use of the PureLink
Quick Plasmid Miniprep kit (Invitrogen, CA, USA) and PCR was performed with forward
primer 5’-AAAAAAGGATCCGCCACCATGACCATCCTTTTCCTTACTATGG-3’ and reverse
primer 5’-GCCCTTACTAGTCTATCTTCCCCTTTTAATGGTCAGT-3’. Purified PCR prod-
ucts were ligated in the rAAV transfer plasmids[37] through BamH1 and Spe1 restriction sites.
The resulting BDNF-rAAV plasmids were transformed into Max Efficiency Stbl2 competent
cells (Invitrogen, CA, USA). Plasmids were isolated from positive clones using the GenElute
Plasmid Miniprep kit (Sigma-Aldrich, MO, USA) and the construct was sequence verified
before viral vector production.
The adeno-associated viral vector serotype 2/1 containing the mouse BDNF gene under
control of a general cytomegalovirus (CMV) promoter (rAAV2/1-CMV-BDNF) and the con-
trol enhanced green fluorescent protein (eGFP)-expressing vector (rAAV2/1-CMV-eGFP)
were produced by the Viral Vector Core of KU Leuven. The vector production process has
been described in detail by Van der Perren et al.[38].
To induce unilateral overexpression of BDNF in the SC, 1 μl rAAV2/1-CMV-BDNF was
stereotactically delivered into the right SC at 3.16E11 GC/ml, using the Nanoject II micro-
injector (Drummond Scientific Company, PA, USA). Control groups received 1 μl injection of
rAAV2/1-CMV-eGFP vector at 3.25E11 GC/ml. Coordinates for mouse right SC were antero-
posterior -3.3 mm and mediolateral +0.4 mm relative to Bregma, and dorsoventral -1.3 mm
from the dura.
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Detection of BDNF and TrkB levels
Sample processing and protein concentration. Animals were anesthetized with sodium
pentobarbital (200 mg/kg body weight, Nembutal, Ceva Sante Animale, France) prior to cervi-
cal dislocation. Retinas and SCi were dissected, snap-frozen, and homogenized in RIPA buffer
(25 mM Tris-HCl, 150 mMNaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% sodium dodecyl
sulfate, pH 7.6) containing a protease and phosphatase inhibitor cocktail (Thermo scientific,
MA, USA). Protein concentrations were determined with the Qubit Protein Assay (Molecular
probes, Invitrogen, CA, USA) and samples were stored at -80°C.
Western blotting. Levels of mBDNF, TrkB-FL, and TrkB-T1 were detected in the retina
and SC samples using western blotting. Equal amounts of the sample (retina: BDNF 120 μg,
TrkB 50 μg; SC: BDNF 60 μg, TrkB 20 μg) were loaded onto 4–12% Bis-Tris polyacrylamide
gels (BioRad Laboratories, CA, USA) and transferred to polyvinylidene difluoride (PVDF)
membranes (BioRad Laboratories, CA, USA). The membrane was incubated for 2 h in 5% ECL
Blocking Agent (GE Healthcare, UK) in 0.01 M tris buffered saline (TBS). Overnight incuba-
tion with primary antibody, polyclonal rabbit anti-BDNF (1:500, sc-546, Santa Cruz Biotech-
nology, TX, USA) or polyclonal rabbit anti-TrkB (1:1500, 07–225, Millipore, MA, USA), was
followed by 45 min incubation with horseradish peroxidase (HRP)-conjugated goat anti-rabbit
IgG (1:10,000, Dako, Denmark). Specific protein bands were visualized using the luminol-
based enhanced chemiluminescence kit (SuperSignal West Dura, Thermo Scientific, MA,
USA). In order to normalize detected amounts of mBDNF or TrkB to the total amount of pro-
tein loaded, LavaPurple (Gelcompany, CA, USA) total protein stain was performed prior to
primary antibody incubation. Specific protein bands and LavaPurple staining were imaged
with the ChemiDoc MP Imaging System (BioRad Laboratories, CA, USA) and optical density
analyses were performed using Image Lab 4.1 software (BioRad Laboratories, CA, USA).
ELISA. Total BDNF levels, including both pro- and mature forms, were quantified based
on standard sandwich enzyme-linked immunosorbent assay (ELISA) technology by means of
the Mouse BDNF ELISA kit (KA0331, Abnova, Taiwan). Data analyses were performed with
Skanit 3.1 software (Thermo Scientific, MA, USA).
Immunohistochemistry
Tissue processing. Animals were anesthetized through i.p. administration of sodium pen-
tobarbital (200 mg/kg body weight, Nembutal, Ceva Sante Animale, France) and transcardially
perfused with 0.9% NaCl, followed by 4% phosphate buffered paraformaldehyde (PFA, Acros
Organics, NJ, USA) for standard immunohistochemistry (IHC). Following perfusion, eyes
were enucleated and fixed for 1 h in 4% PFA. Next, retinas were dissected, flat mounted, and
post-fixed for 1 h in 4% PFA. Brains were dissected and post-fixed overnight in 4% PFA. For
BDNF IHC, perfusion was performed using 4% phosphate buffered PFA containing 0.4%
parabenzoquinone (pBQ, Sigma-Aldrich, MO, USA), followed by brain post-fixation for 2 h
in the same solution. The SC brain region was sectioned into 50 μm coronal sections using the
Micron H650 vibratome (Thermo Scientific, MA, USA).
Immunohistochemistry on brain sections. For general IHC, free floating coronal SC sec-
tions were rinsed in PBS containing 0.1% Triton X-100 (Fisher Scientific, NY, USA) (PBST0.1)
and incubated for 1 h in PBST0.1 containing 20% goat pre-immune serum (Invitrogen, CA,
USA), followed by incubation with primary antibodies, diluted in PBST0.1 and 10% goat pre-
immune serum (Table 1). After rinsing and incubation for 2 h with secondary antibody (Alexa
Fluor-488/568-conjugated goat anti-rabbit and/or goat anti-mouse IgG, Invitrogen, CA, USA),
diluted 1:200 in PBST0.1, sections were rinsed and cell nuclei were stained with 4’,6-diami-
dino-2-phenylindole (DAPI, 1 μg/ml in PBS, Dako, Denmark). Next, the tissue sections were
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mounted on gelatin-coated microscopy slides, and cover slipped with mowiol mounting
medium (10% mowiol 4–88 (Sigma-Aldrich, MO, USA), 40% glycerol, 0.1% 1,4-diazabicyclo-
[2,2,2]-octane in 0.2 M Tris-HCl [pH 8.5]).
For NeuN IHC, before incubation with goat pre-immune serum, endogenous peroxidases
were blocked via incubation in 0.3% H2O2 (in methanol) for 20 min, followed by thorough rins-
ing. After overnight primary antibody incubation, washing, and 45 min incubation with biotiny-
lated goat anti-rabbit IgG (1:300 in PBST0.3, DAKO, Denmark), tyramid signal amplification
via the TSA™ Cy3 System (NEL744001KT, Perkin Elmer, MA, USA) was used.
Immunofluorescent labeling was visualized using the FV1000-D laser confocal scanning
microscope (Olympus Corporation, Japan), controlled by Fluoview 4.0 software.
RGC visualization and counting on whole-mount retinas. IHC labeling for Brn3a, a
POU-domain transcription factor and reliable marker for RGCs[8, 27, 28], was performed on
whole-mount retinas. Retinas were washed in PBS containing 0.5% Triton X-100 (PBST0.5)
and frozen at -80°C for 15 min to enhance permeability. After rinsing in PBST0.5, retinas were
incubated overnight with goat anti-Brn3a (1:500, sc-31984, Santa Cruz Biotechnology, TX,
USA) diluted in PBS containing 2% Triton X-100 (PBST2.0) and 2% donkey pre-immune
serum (Invitrogen, CA, USA). Subsequently, retinas were rinsed in PBST0.5 and incubated for
2 h with polyclonal Alexa Fluor-488-conjugated donkey anti-goat IgG (Invitrogen, CA, USA),
diluted 1:500 in PBST2.0. Retinas were then rinsed in PBST0.5 and PBS before being mounted
on glass slides with mowiol mounting medium. The stained retinal whole-mounts were imaged
with the FV1000-D laser confocal scanning microscope (Olympus Corporation, Japan) con-
trolled by Fluoview 4.0 software.
RGC density (number of RGCs/mm2) was calculated on images of the entire retinal whole-
mount, using an in-house script developed for freely available Fiji software[40] (National Insti-
tute of Health, MD, USA) (Geeraerts et al., manuscript submitted to Exp Eye Res). Subse-
quently, RGC density data were transformed into pseudocolor isodensity maps to have a better
view of the spatial differences in RGC density[31, 41, 42], with the pseudocolor scale represent-
ing low (dark blue) to high (red) RGC densities.
In vitro secretion of vector-based BDNF by HEK cells
To verify cellular secretion of BDNF upon transduction with the BDNF-expressing vector,
human embryonic kidney 293T (HEK293T) cells (American Type Culture Collection, VA,
USA) were cultured in Dulbecco modified Eagle medium (DMEM, Invitrogen, CA, USA) sup-
plemented with 8% fetal calf serum (Invitrogen, CA, USA) and gentamicin (Sabex, Canada),
plated at 100,000 cells per well (24-well plates) in 500μl medium. HEK293T cells were trans-
duced with either the rAAV2/1-CMV-BDNF or rAAV2/1-CMV-eGFP vector. After 48 h incu-
bation with medium containing vector at 4.29E9 GC/ml, the cells were transferred to 6-well
Table 1. List of primary antibodies used for fluorescent IHC on coronal SC sections.
Primary antibody Labels Incubation time and dilution Reference
Polyclonal rabbit anti-eGFP eGFP 24 h, 1:10,000 In house made [39]
Monoclonal mouse anti-GFAP (Reactive) astrocytes 24 h, 1:1,000 G3893, Sigma-Aldrich, MO, USA
Monoclonal mouse anti-NeuN Neuronal nuclei 24 h, 1:200 MAB377, Millipore, Germany
Polyclonal rabbit anti-BDNF Pro- and mBDNF 48 h, 1:500 sc-546, Santa Cruz Biotechnology, TX, USA
Key: IHC, immunohistochemistry; SC, superior colliculus; eGFP, enhanced green fluorescent protein; GFAP, glial fibrillary acidic protein; NeuN, neuronal
nuclei; BDNF, brain-derived neurotrophic factor; mBDNF, mature form of brain-derived neurotrophic factor.
doi:10.1371/journal.pone.0142067.t001
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plates and medium was harvested 24 h and 72 h later. To quantify BDNF levels in the medium,
the Mouse BDNF ELISA kit (KA0331, Abnova, Taiwan) was used according to the manufac-
turer’s guidelines. Analyses were performed with Skanit 3.1 software (Thermo Scientific, MA,
USA).
To estimate transduction efficiency, eGFP vector-transduced cells were fixed for 15 min in
4% phosphate buffered PFA and incubated for 30 min with 1 μg/ml DAPI in PBS (Dako, Den-
mark) for nuclear staining. The DAPI and eGFP signals were visualized with the FV1000-D
laser confocal scanning microscope (Olympus Corporation, Japan). The percentage of eGFP-
expressing cells was calculated over 400 randomly chosen DAPI+ cells.
Ex vivo validation of vector derived BDNF activity
Retinal explants. To validate the bio-activity of vector-derived BDNF, postnatal retinal
explants were cultured in medium supplemented with conditioned medium derived from
transduced HEK293T cells, and neurite outgrowth was studied. Retinal explants were isolated
as previously described[43, 44]. Briefly, 750 μm explants were punched from dissected retinas
from postnatal mouse pups (P3) and cultured in poly-L-lysin and laminin-coated wells (Nun-
clonTM delta surface, Thermo Scientific, Rochester, NY, USA) for 3 d. Explants were cultured
in Neurobasal™-A medium (Invitrogen, CA, USA), containing 0.4% methylcellulose (Sigma-
Aldrich, MO, USA), 1% penicillin/streptomycin, 0.2% fungizone, 0.5% L-glutamine and 2% B-
27 supplement for retina (all from Invitrogen, CA, USA). The explant culture medium was
supplemented with 1) conditioned medium from BDNF vector-transduced HEK293T cells, to
a final concentration of 50 ng/ml BDNF, 2) conditioned medium from eGFP vector-transduced
HEK293T cells, or 3) with recombinant BDNF in a final concentration of 50ng/ml (Peprotech
Laboratories, UK). Every day, half of the culture medium was replaced with fresh medium,
containing the same concentration of compound or vehicle.
Immunohistochemistry on retinal explants and neurite outgrowth analysis. Explants
were fixed in 4% phosphate buffered PFA and neurite outgrowth was visualized by immunos-
taining for β-tubulin using the monoclonal mouse anti-β-tubulin III antibody (1:500, T8660
clone SDL.3D10, Sigma-Aldrich, MO, USA), as described[43, 44]. β-tubulin III stained
explants were imaged by the FV1000-D laser confocal scanning microscope controlled by Fluo-
view 4.0 software (Olympus Corporation, Japan) and analyzed using Axiovision software
(Zeiss, Germany). Automated analysis of axonal outgrowth was performed by measuring the
neurite outgrowth area, as previously described[43, 44].
Statistics
All data are presented as mean ± SEM. Outliers were determined via a Grubbs test and
excluded from further analyses. A normal distribution was verified using the Kolmogorov-
Smirnov test and parallel equal variance between groups was tested. If the test requirements
were fulfilled, a parametrical ANOVA was used, followed by bonferroni post hoc tests. When
criteria for parametric statistics were not fulfilled, a non-parametrical Kruskal-Wallis analysis
with a Mann-Whitney U rank sum test for pairwise comparison of independent samples was
applied. Additionally, Student’s t-test for pairwise comparison was used. For all tests, a proba-
bility level (α-level was set to 0.05) of<0.05 was accepted as statistically significant ( p<0.05,
 p<0.01,  p<0.001). All statistical analyses were performed using GraphPad Prism S5
(GraphPad Software, CA, USA).
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Results
RGC degeneration profiles in the mouse ONC and OHTmodels
Animal models of glaucoma are essential to elucidate the underlying pathophysiological mech-
anisms and to develop therapeutic strategies to halt or even reverse disease progression[32].
Therefore, our first goal was to outline RGC degeneration profiles in two commonly used
experimental mouse models of glaucoma, the ONC and LP-induced OHT model, using Brn3a
IHC at several time points post-injury.
The ONC induced with self-closing cross-action forceps resulted in a complete crush of the
optic nerve and all RGC axons, as visualized by hematoxylin and eosin staining and RT97 IHC
on optic nerve cross-sections, harvested at 1 h after ONC (data not shown). The onset of ONC-
induced RGC death was situated between 4 dpi (3,102 ± 197.1 RGC/mm2, N = 5, p>0.05) and
5 dpi (2,550 ± 36.5 RGC/mm2, N = 3, p<0.001) (Fig 1A), while at 3 dpi, RGC densities
(3,429 ± 20.8 RGC/mm2, N = 4) were similar to the naive condition (3,394 ± 29.4 RGC/mm2,
N = 9). Between 5 and 21 dpi, RGC degeneration progressed, with RGC density measured at 7,
14, and 21 dpi being 1,392 ± 59.3 RGC/mm2 (N = 10), 756 ± 99.2 RGC/mm2 (N = 6), and
376 ± 12.7 RGC/mm2 (N = 3), respectively. At all time points, the contralateral eyes showed
RGC densities comparable to naive retinas (on average 3,457 ± 67.8 RGC/mm2, N = 22). ONC-
induced RGC degeneration was diffuse throughout the retina (Fig 1B).
In the OHT model, from 24 h post-LP onwards, a significant increase in IOP was measured,
resulting in an IOP of 41.9 ± 1.6 mmHg, compared to 12.8 ± 0.1 mmHg in the control eye.
This OHT was sustained for at least 3 d, after which the IOP gradually declined to baseline lev-
els by 7 d post-LP (data not shown), a pattern being in line with previous publications using
this model[2, 30, 31]. RGC densities in the LP eyes were significantly reduced (p<0.001) at 5
dpi (3,010 ± 128.0 RGC/mm2, N = 8), 7 dpi (2,086 ± 140.9 RGC/mm2, N = 12), 14 dpi
(470 ± 42.9 RGC/mm2, N = 14), and 21 dpi (337 ± 48.9 RGC/mm2, N = 9), compared to naive
animals (4,065 ± 107.0 RGC/mm2, N = 10) (Fig 2A). RGCs died progressively between 5 and
14 dpi, while the RGC density remained stable thereafter. The contralateral eyes showed RGC
densities comparable to naive retinas (on average 3,723 ± 51.4 RGC/mm2, N = 24). On top of
diffusely distributed RGC death all over the retina, a pie-shaped sectorial degeneration pattern
was observed (Fig 2B).
Thus, both the ONC and OHT models elicited progressive RGC degeneration. In both mod-
els, RGC loss occurred diffusely throughout the retina, however, only in the OHT model pie-
shaped sectors of severe RGC death superposed the diffuse degeneration pattern.
Expression of BDNF and TrkB in experimental glaucoma
In order to contribute to a better understanding of the role of neurotrophin signaling in glau-
coma, the effect of experimental glaucoma on BDNF and TrkB levels in the glaucomatous ret-
ina and the SC contralateral to the experimental eye, was examined via ELISA for total BDNF
levels and western blotting for TrkB-FL and TrkB-T1.
In the ONC model, total BDNF levels in the retina increased marginally from 6 h post-ONC
onwards, reaching significance at 3 dpi (+79 ± 15%, N = 3) to 5 dpi (+62 ± 16%, N = 4), and
attenuating afterwards (Fig 3A). The retinal TrkB-FL levels increased slightly upon ONC (Fig
3B), with a maximum and the only significant difference at 5 dpi (+95 ± 23%, N = 4). TrkB-T1,
in contrast, showed a larger increase, reaching peak levels between 24 h (+223 ± 66%, N = 3)
and 5 d (+235 ± 151%, N = 4) post-ONC, however only the 24 h value differed significantly
from the naive condition. In the SC, total BDNF levels (Fig 3C) were significantly enhanced as
soon as 6 h post-ONC (+70 ± 12%, N = 4) and slowly decreased to baseline levels thereafter,
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remaining significantly different from naive until 3 dpi (+55 ± 18%, N = 4). Collicular TrkB-FL
and TrkB-T1 levels (Fig 3D) followed a very similar pattern after ONC induction, increasing
from 6 hpi onwards (TrkB-FL +158 ± 34%, TrkB-T1 +123 ± 17%, N = 4) with the turning
point situated around 3 d post-ONC (TrkB-FL +192 ± 74%, TrkB-T1 +159 ± 91%, N = 4).
Fig 1. ONC yields progressive RGC degeneration, diffusely distributed throughout the retina. (A) ONC-induced RGC death in the ONC eye (OS) is
progressive between 4 and 21 dpi. (B) Representative images of naive or injured retinas in which RGCs are visualized through Brn3a IHC. Right panels show
isodensity maps with the numbers indicating percentages of surviving RGCs compared to naive. Scale bars left: 500 μm, middle: 50 μm. Key: ONC, optic
nerve crush; RGC, retinal ganglion cell; IHC, immunohistochemistry; dpi, days post-injury; OS, oculus sinister; OD, oculus dexter.
doi:10.1371/journal.pone.0142067.g001
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Strikingly, in the retina TrkB-FL is the most abundant form, while in the SC, TrkB-T1 is more
represented.
For the OHT model, patterns of BDNF and TrkB levels in the retina and SC were different
from the ONCmodel. In the retina of OHT eyes, no changes in the total BDNF level, neither in
the TrkB-FL and TrkB-T1 levels, could be detected, in comparison to naive eyes (Fig 4A and
Fig 2. LP-induced OHT yields progressive diffuse and sectorial RGC degeneration. (A) OHT induces
progressive RGC degeneration in the LP eye (OS), reaching final levels at 14 dpi. (B) Representative images
of naive or injured retinas in which RGCs are visualized through Brn3a IHC. Right panels show isodensity
map and the numbers indicate percentages of surviving RGCs compared to naive. Scale bars left: 500 μm,
middle: 50 μm. Key: OHT, ocular hypertension; LP, laser photocoagulation; RGC, retinal ganglion cell; IHC,
immunohistochemistry; dpi, days post-injury; OS, oculus sinister; OD, oculus dexter.
doi:10.1371/journal.pone.0142067.g002
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4B). In the SC, total BDNF levels were not noticeably altered by OHT induction either (Fig
4C). However, OHT induction did induce a slight but significant decrease in collicular TrkB-FL
levels (Fig 4D), with the lowest point situated at 5 dpi (-36 ± 6%, N = 8). TrkB-T1 levels fol-
lowed a similar decreasing pattern in the OHT model, however, this decline did not reach
significance.
Overall, retinal and collicular BDNF and TrkB levels were differentially altered after experi-
mentally induced glaucoma in the ONC and OHT models.
Tackling glaucoma from within the brain: a viral vector based approach
According to the neurotrophin deprivation hypothesis, disruption of retrograde delivery of
trophic support is one of the main triggers that induces apoptotic signaling in the RGCs in
glaucoma[5, 45]. With the cellular response to neurotrophin-receptor interaction being
Fig 3. Endogenous BDNF and TrkB levels in retina and SC at various time points after ONC. (A) In the retina, the total BDNF levels, analyzed via
ELISA, rise upon ONC, reaching a peak at 3 to 5 d, attenuating afterwards. (B) The retinal TrkB-FL levels only slightly increase in the ONCmodel, while
TrkB-T1 inclines more, reaching peak levels between 24 h and 5 d post-ONC. (C) In the SC, total BDNF concentrations are enhanced as soon as 6 h post-
ONC and slowly decrease to baseline levels thereafter. (D) Collicular TrkB-FL and TrkB-T1 levels follow a very similar increase-decrease pattern after ONC
induction, with the turning point situated around 3 d post-ONC. Key: BDNF, brain-derived neurotrophic factor; TrkB, tropomyosin receptor kinase B; TrkB-FL,
TrkB full-length form; TrkB-T1, TrkB truncated form 1; SC, superior colliculus; ONC, optic nerve crush.
doi:10.1371/journal.pone.0142067.g003
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suggested to be different depending on the neuronal compartment from where the signal is
initiated (i.e. in the cell body, in the axon terminals, or on the dendrites)[18, 23], it seems plau-
sible to hypothesize that delaying or preventing RGC death could be better achieved by inter-
fering with their target areas. We intended to deliver a proof-of-concept for this hypothesis,
by studying the effect of local neurotrophin delivery in the SC on the RGC survival in different
glaucoma models. To induce a chronic neurotrophin upregulation in the SC, viral vector tech-
nology was used.
Validation of viral vector based BDNF overexpression in vivo. Based on the fact that the
applicability of different viral vector systems depends on the experimental setup, tissue, and
species[46, 47], we first defined the optimal vector system for local delivery to the mouse SC
[48]. Thereto, the viral vector of choice was determined by comparing the induced glial
response, transduction efficiency, cell tropism, and retrograde transduction capacity of differ-
ent rAAV2/x serotypes upon delivery to the SC. Since our goal was to study the effect of
Fig 4. Endogenous BDNF and TrkB levels in retina and SC at various time points after OHT induction. (A) In the retina, the total BDNF levels do not
change by OHT induction. (B) The retinal levels of TrkB-FL and TrkB-T1 do not show significant alterations in the OHTmodel. (C) In the SC, the total BDNF
levels are not altered by OHT induction. (D) Collicular TrkB-FL and TrkB-T1 levels follow a very similar, slightly decreasing pattern after OHT induction. Key:
BDNF, brain-derived neurotrophic factor; TrkB, tropomyosin receptor kinase B; TrkB-FL, TrkB full-length form; TrkB-T1, TrkB truncated form 1; SC, superior
colliculus; OHT, ocular hypertension.
doi:10.1371/journal.pone.0142067.g004
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enhanced neurotrophin release within the SC on RGC survival in glaucoma models, it seemed
essential to pick a viral vector that effectively targets collicular cells, but does not result in
retrograde transduction of retinal cells. As vector rAAV2/1 was found to elicit low astroglial
reactivity and to exhibit high transduction efficiency in mouse SC neurons (Fig 5A) without
retrogradely targeting the retina, this vector was chosen for all further experiments. For a
more detailed description (comparison of the viral serotypes tested) of these results we refer to
S1 Fig.
Next, the rAAV2/1-CMV-BDNF vector, developed to induce collicular neurotrophin over-
expression, was validated in vivo. Unilateral delivery of the rAAV2/1-CMV-BDNF vector into
the mouse SC resulted in extensive upregulation of BDNF expression, visualized through IHC
(Fig 5B) at two weeks post-injection, as compared to the non-injected hemisphere. In addition,
total BDNF levels, quantified using ELISA at 18 d post vector delivery (Fig 5C) were highly
augmented in BDNF vector-transduced SC (5,780 ± 453 pg BDNF/mg protein, N = 7) as com-
pared to both non-transduced SCi in the same animals (716 ± 162 pg BDNF/mg protein,
N = 7) or to eGFP vector-transduced SCi (407 ± 91 pg BDNF/mg protein, N = 5). Since pro-
and mature forms of BDNF partially induce divergent signaling cascades, it was important to
verify whether transgenically expressed pro-BDNF was transformed into mBDNF. This was
validated through western blotting, in which a clear upregulation of the 14 kDa mBDNF band
was identified in transduced SC samples derived from BDNF vector-injected mice, as com-
pared to both the internal control (+567 ± 168.4%, N = 5) and eGFP vector-transduced SC of
external control animals (+462 ± 116.4%, N = 5) (Fig 5D). Thus, mBDNF was clearly upregu-
lated in the mouse SC upon vector delivery in vivo.
In vitro/ex vivo validation of vector-derived BDNF activity. The characteristics of vector-
derived BDNF were investigated in more detail in vitro/ex vivo. To verify whether transgenically
expressed BDNF could be secreted by transduced cells, BDNF concentrations were measured in
medium harvested from cultured HEK293T cells, transduced at a success rate of 81.2% with
either the BDNF- or eGFP-expressing viral vector. As expected, BDNF levels were much higher
(p<0.001, N = 4) in medium harvested from BDNF vector-transduced cells, both at 24 h
(298.45 ± 19.51 ng/ml) and at 72 h (264.03 ± 55.24 ng/ml) post-transduction, as compared to
medium harvested from cells transduced with the control vector at 24 h (0.01 ± 0.00 ng/ml) and
72 h (0.01 ± 0.00 ng/ml) post-transduction (Fig 5E). Thus, viral vector-derived BDNF is secreted
by transduced HEK293T cells in vitro. Next, using the well-established retinal explant model,
bio-activity of the vector-derived BDNF was verified. Explants incubated with medium supple-
mented with recombinant BDNF (rBDNF, N = 11) or with conditioned medium from BDNF
vector-transduced HEK293T cells (vBDNF, N = 6) showed enhanced neurite outgrowth com-
pared to control explants, which were cultured in medium supplemented with equal amounts of
conditioned medium from eGFP vector-transduced HEK293T cells (eGFP, N = 8) (Fig 5F).
Thus, viral vector-derived BDNF was shown to be bio-active.
Intracollicular BDNF delivery is not neuroprotective to RGCs in the ONC and OHT
model. In the following experiments, we envisioned to counteract glaucomatous RGC degen-
eration via brain-directed treatment, by stimulating the pro-survival colliculoretinal signaling.
Thereto, the validated rAAV2/1-CMV-BDNF vector was used to upregulate BDNF in the
mouse SC in an attempt to induce long-distance neurotrophic protective effects on the RGCs
in both models of experimental glaucoma.
Two weeks after intracollicular vector delivery to induce chronic BDNF or eGFP expression,
mice received unilateral ONC or OHT induction and were sacrificed 7 d later. First, BDNF and
eGFP expression was validated via IHC in three randomly chosen animals of each group. For
each of these mice, a robust transgene expression was observed throughout the SC (data not
shown, similar to results of vector validation shown in Fig 5B). Next, RGC survival was
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evaluated. Within the ONCmodel, RGC counts were not found to be different between treat-
ment groups (Fig 6A), with RGC densities of 1,326 ± 54.7 RGCs/mm2 and 1,170 ± 89.3 RGCs/
mm2 measured in ONC eyes of the BDNF vector-transduced group (N = 8) and the eGFP
group (N = 10), respectively. Also, for the OHTmodel, in which IOP patterns were very similar
Fig 5. Validation of expression, secretion, and activity of viral vector-derived BDNF. (A) The rAAV2/1-CMV-eGFP vector almost exclusively induces
eGFP expression in neurons (NeuN) and not in glial cells (GFAP). Filled arrowheads point towards double-labeled cells. Scale bars: 20 μm. (B) Unilateral
rAAV2/1-CMV-BDNF vector-induced BDNF upregulation is visualized through IHC. Scale bar: 200 μm. (C) Total BDNF levels in BDNF vector-transduced SC
are sharply enhanced compared to non-transduced SC in the same animals (internal control) and to both SCi of eGFP vector-transduced mice, quantified via
ELISA. (D) Western blot analyses show an upregulation of mBDNF levels in BDNF vector-transduced SC compared to internal controls and to eGFP vector-
transduced animals. (E) In contrast to HEK293T cells transduced with the eGFP control vector, HEK293T cells transduced with BDNF vector secrete large
amounts of BDNF in the culture medium, as quantified by ELISA on medium harvested 24 h and 72 h post-transduction. (F) Retinal explants cultured in
medium supplemented with recombinant BDNF (rBDNF) or vector-derived BDNF (vBDNF) show enhanced neurite outgrowth areas compared to control
explants (eGFP). N = number of explants, derived from three mice. Key: BDNF, brain-derived neurotrophic factor; mBDNF, mature form of BDNF; eGFP,
enhanced green fluorescent protein; DAPI, 4’,6-diamidino-2-phenylindole; SC, superior colliculus; rAAV2/1, recombinant adeno-associated viral vector
serotype 2/1; CMV, cytomegalovirus promoter; IHC, immunohistochemistry; ELISA, enzyme-linked immunosorbent assay; ONC, optic nerve crush; OHT,
ocular hypertension; dpi, days post-injury; HEK293T, Human embryonic kidney cell line.
doi:10.1371/journal.pone.0142067.g005
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between groups (Fig 6C), no differences were detected in RGC survival rates between BDNF
and eGFP groups (Fig 6B). Measured RGC densities in the hypertensive eye were 2,386 ± 214.7
RGCs/mm2 for the BDNF group (N = 6) and 2,473 ± 192.2 RGCs/mm2 for the eGFP group
(N = 6).
Thus, despite a clear BDNF upregulation in the SC, the viral vector-mediated brain treat-
ment did not exert neuroprotective effects on RGCs in the present experimental glaucoma
models.
Explanation for the unexpected hurdles in the viral vector based
treatment
Intravitreal BDNF administration is neuroprotective in the ONCmodel. We then
sought for an explanation for these disappointing results. First, we verified whether the experi-
mentally induced RGC degeneration in our models leaves a window to induce neuroprotection.
Thereto, mice that were subjected to the ONC model received local BDNF treatment through
ivt injection, based on previous reports[8–10, 14].
A single ivt administration of recombinant mBDNF at the time of ONC resulted in 10%
neuroprotection at 7 d after ONC (Fig 6D). Brn3a+ RGC density was 2,125 ± 52.7 RGCs/mm2
and 1,658 ± 65.4 RGCs/mm2 in BDNF- and vehicle-treated ONC eyes, respectively (N = 4).
Fig 6. Glaucomatous RGC death is counteracted by ivt BDNF administration but not by vector-mediated BDNF upregulation in the SC. (A) At 7 d
post-ONC, no difference is detected in RGC survival between groups with eGFP or BDNF transgene expression in the SC. (B) At 7 d post-OHT induction,
collicular eGFP and BDNF transgene expressing mice show a similar degree of RGC degeneration. (C) IOP elevation in both eGFP and BDNF transgene
expressing groups follow a similar pattern. Key: ivt, intravitreal; RGC, retinal ganglion cell; SC, superior colliculus; OD, oculus dexter; OS, oculus sinister;
BDNF, brain-derived neurotrophic factor; eGFP, enhanced green fluorescent protein; LP, laser photocoagulation; days post-injury. D. One single ivt injection
of BDNF at the time of ONC, leads to a temporarily enhanced RGC survival of 10% at 7 dpi, but not at 14 dpi. E. Repeated ivt BDNF administration at 0, 3,
and 5 dpi could not ameliorate the survival effect obtained with one single injection at 7 dpi. However, triple BDNF treatment at 0, 5, and 10 dpi did result in a
prolonged increase in RGC survival of 4.5% at 14 dpi.
doi:10.1371/journal.pone.0142067.g006
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However, the protective effect was transient, as at 14 dpi, there was no longer a difference in
Brn3a+ RGC counts between BDNF- (700 ± 65.8 RGCs/mm2) and vehicle-treated (710 ± 93.2
RGCs/mm2) ONC eyes (N = 5).
Strikingly, triple BDNF administration at 0, 3, and 5 dpi was not found to enhance the neu-
roprotective effect seen at 7 dpi after a single dose (Fig 6E). Using this repetitive treatment par-
adigm, again, only a 10% reduction in RGC death was detected in BDNF-treated ONC eyes
(1,785 ± 38.7 RGCs/mm2, N = 7) at 7 dpi, as compared to vehicle-injected eyes (1,393 ± 41.9
RGCs/mm2, N = 8). However, ivt BDNF injections at 0, 5, and 10 dpi did slightly prolong the
neuroprotective effect, with 4.5% enhanced survival in the ONC eyes of the BDNF (N = 8) ver-
sus vehicle (N = 4) groups at 14 dpi. RGC densities in ONC eyes were 532 ± 20.2 RGCs/mm2
in BDNF-treated groups versus 389 ± 28.4 RGCs/mm2 in the vehicle group.
Thus, our results confirmed the temporary RGC protective effect of ivt delivered recombi-
nant BDNF in the ONCmodel. Despite its ability to prevent RGC degeneration in the short-
term, the long-term effectiveness of ivt BDNF administration was limited, even when provided
as multiple injections.
Viral vector-induced collicular BDNF overexpression results in neurotrophin desensiti-
zation. Then why did the delivery of BDNF to the SC not have a similar neuroprotective out-
come? To be able to support RGC survival, BDNF, released and activated within the SC, needs
to reach the retina via retrograde transport through the RGC axons. Unfortunately, both
ELISA and western blot analyses of retinal samples (N = 5), dissected at 18 d post collicular
BDNF vector injection, revealed no change in total and mBDNF levels in the retina despite a
clear BDNF overexpression in the SC (Fig 7A and 7B). Possibly, RGCs do not retrogradely
transport the extra BDNF unless additional trophic support is needed, e.g. to counteract injury.
Therefore, retinal BDNF measurements were repeated in animals, in which viral vector injec-
tion was combined with experimentally induced glaucoma. Thereto, mice were subjected to
ONC (N = 3) and OHT (N = 5) at 14 d post vector injection, and samples were processed 4 d
post glaucoma induction. Based on the fact that ELISA is more sensitive than western blotting,
ELISA was the method of choice here. Unfortunately, retinal BDNF levels remained unaltered
upon vector-mediated collicular BDNF overexpression (Fig 7C and 7D). Our data confirmed
the upregulation of retinal BDNF upon ONC described above, but no additional effect of SC
transduction was seen. Overall, we were not able to establish any effect on retinal BDNF levels
upon BDNF upregulation in the SC, in non-injured nor injured eyes. One possible explanation
for this lack of retrograde transport is an abnormal expression or distribution of the TrkB
receptor. Indeed, for its colliculoretinal transport, BDNF needs to bind to its receptor in order
to be internalized into a transport vesicle. Therefore, we determined TrkB-FL and TrkB-T1 lev-
els in both SC and retina upon vector injection. Importantly, at 18 d post vector delivery, vec-
tor-based enhancement of BDNF levels in the SC led to a reduction of TrkB-FL levels in the
BDNF vector-transduced SC (-47 ± 7.3% compared to internal control, N = 4, Fig 8A), while
TrkB-T1 levels did not change (N = 4, Fig 8B). Viral vector-derived BDNF did not affect retinal
TrkB-FL (NBDNF = 4, NeGFP = 5, Fig 8D) and TrkB-T1 levels (N = 5, Fig 8E).
Thus, our data indicated that in response to vector-based BDNF upregulation in the SC,
TrkB-FL levels were downregulated in the transduced SC, thereby possibly reducing complex
formation between BDNF and TrkB-FL and hence colliculoretinal transport of BDNF.
Discussion
The main objective of the performed experiments was to study the contribution of BDNF, the
most commonly studied neurotrophin, to glaucoma disease progression, using two experimen-
tal mouse glaucoma models, commonly applied to mimic glaucoma pathology.
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RGC degeneration patterns in the ONC and OHTmodel
We first characterized the RGC degeneration pattern for both models. ONC-triggered retinal
neurodegeneration had an onset between 4 and 5 dpi, progressively evolving towards a survival
ratio of 12% at 21 dpi. RGC loss elicited by ONC appeared diffuse and affected the whole ret-
ina, without any evidence of a sectorial pattern, which is in line with literature[28, 49]. Differ-
ent RGC degeneration rates upon ONC have been reported by others, reasoned to be caused by
variations in experimental procedures, such as the distance between the crush site and the
globe[49], and the duration and force of the crush[32], or the method of RGC visualization and
quantification[50].
Within the OHT model, characterized by a temporary elevation of the IOP, RGC loss
occurred diffusely throughout the retina with pie-shaped sectors of severe RGC death super-
posing the diffuse degeneration pattern, as clearly demonstrated by the isodensity maps. This
pattern reflects a typical glaucomatous retinal degeneration pattern described in human
patients[51] and several OHT-related animal models[2, 31, 52–54]. Although IOP elevation
Fig 7. Viral vector-derived BDNF in the SC is not transported towards the retina. (A) Unilateral vector-based BDNF upregulation in the SC does not lead
to changes in total BDNF levels in the retina, ipsilateral nor contralateral to the transduced SC, as measured via ELISA. (B) Western blot analysis for
detection of mBDNF does not show any difference between retina ipsilateral nor contralateral to the BDNF or eGFP vector-transduced SC. (C) Total retinal
BDNF levels in ONC or non-ONC eyes, contralateral to the transduced SC, are similar in mice injected with rAAV2/1-CMV-BDNF or rAAV2/1-CMV-eGFP.
(D) Similar results as shown in C. were obtained using OHT induction instead of ONC. Key: BDNF, brain-derived neurotrophic factor; mBDNF, mature form of
BDNF; ELISA, enzyme-linked immunosorbent assay; eGFP, enhanced green fluorescent protein; ONC, optic nerve crush; OHT, ocular hypertension; dpi,
days post-injury.
doi:10.1371/journal.pone.0142067.g007
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was acute and transient, which may be considered a disadvantage when keeping in mind the
chronic nature of human glaucoma, OHT-induced degeneration continued after IOP had nor-
malized. Indeed, a decrease in RGC density was apparent with increasing time post-LP. Other
studies, using the same model in CD-1 mice, reported Brn3a-based survival rates that are in
accordance with our results[30, 31]. Of note, care must be taken when comparing various
reports describing survival rates upon OHT-induced by LP of the perilimbal and episcleral
Fig 8. Collicular and retinal TrkB levels upon unilateral viral vector delivery to the SC. (A) Western blot analysis shows reduced TrkB-FL levels in
BDNF vector-transduced SC compared to both internal controls and eGFP vector-transduced animals. (B) Collicular TrkB-T1 levels are not influenced by
unilateral SC vector transduction. (C) Western blot for TrkB-FL and TrkB-T1 in the SC 18 d after viral vector delivery showing representative bands for the
graphs in A and B, with 1) internal control SC of eGFP vector injected mice, 2) SC transduced with eGFP vector, 3) internal control SC of BDNF vector-
transduced mice, 4) BDNF vector-injected SC. (D, E) Upon unilateral SC transduction with eGFP or BDNF vector, no differences in full-length (D) or
truncated (E) forms of TrkB are detected in retinas ipsilateral or contralateral to the transduced SC. F. TrkB-FL and TrkB-T1 western blot detection in the
retina 18 d after viral vector delivery, representative bands for the graphs in C and D, with 1) internal control retina ipsilateral to eGFP vector-injected SC, 2)
retina contralateral to the SC transduced with eGFP vector, 3) internal control retina ipsilateral to BDNF vector-transduced SC, 4) retina contralateral to
BDNF vector-injected SC. Key: SC, superior colliculus; BDNF, brain-derived neurotrophic factor; TrkB, tropomyosin receptor kinase B; TrkB-FL, TrkB full-
length form; TrkB-T1, TrkB truncated form 1, eGFP, enhanced green fluorescent protein.
doi:10.1371/journal.pone.0142067.g008
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veins in mice, since the use of different mouse strains[54] or various methods to label RGCs
[52], might lead to discrepancies in the reported degeneration profiles.
Endogenous expression of BDNF and TrkB in experimental glaucoma
Experimental glaucoma affects BDNF and TrkB levels in the retina. The current study,
investigating levels of BDNF together with its main receptor TrkB in the retina and SC in two
mouse models of experimentally induced glaucoma, firstly demonstrated that retinal BDNF
levels were elevated after ONC (Fig 9). ONC induces immediate axonal damage that results in
blockage of the retrograde delivery of neurotrophins from the brain. Rapid upregulation of
endogenous BDNF expression in the retina may thus act as a natural protection mechanism to
overcome neurotrophin transport deficits[6, 55]. In line with our results, temporary upregula-
tion of BDNF[55] and also of downstream actors within neurotrophin-induced pathways[56],
have been previously described in the ONCmodel; however, others reported no effect of ONC
on retinal BDNF concentrations[57]. Furthermore, the retinal levels of both the TrkB-FL and
TrkB-T1 isoforms increased upon ONC, with TrkB-T1 showing the most pronounced increase.
This might seem contrary to the study of Cheng et al., describing reduced TrkB levels in rat
RGCs after optic nerve transection (ONT)[58]. However, it is important to note that the results
of the present work reflect findings from the whole retina, and that responses unique to RGCs
may be diluted by contributions from other TrkB-expressing retinal cells, e.g. Müller glia[59].
Although both BDNF and TrkB concentrations increased in the retina after ONC, this did
not protect RGCs from dying, possibly because the TrkB upregulating effect was the highest for
the TrkB-T1 isoform. The expected neuroprotective role of the extra BDNF might be attenu-
ated because of sequestration by TrkB-T1 expressing glia[22] or because of a shift towards
TrkB-T1 in the TrkB ratio in RGCs.
In contrast to ONC, BDNF and TrkB levels in the retina were not affected by OHT in our
study (Fig 9). Although OHT has also been described to negatively influence RGC axonal
transport, leading to neurotrophin deprivation[6], this effect is believed to be less direct com-
pared to ONC. The observed differences in endogenous expression of BDNF and TrkB within
the 2 glaucoma models then indeed hint to a (partial) preservation of axonal transport in the
OHT model as compared to ONC at the included time points. Of note, while the ELISA data
revealed stable total BDNF levels, changes in the pro-/mBDNF ratio cannot be excluded.
Literature describing the effect of OHT on retinal BDNF signaling is confusing and far from
complete, with various studies, using a number of rodent OHT models, showing assorted
effects of elevated IOP on BDNF and TrkB mRNA and protein levels in the retina and ONH
(Fig 9)[13, 60–63]. These discrepancies in the existing reports are probably the resultant of dif-
ferences in how OHT is induced and the level of the resultant IOP elevation, as well as of the
techniques applied for sample processing and subsequent mRNA and protein detection.
Experimental glaucoma affects BDNF and TrkB levels in the superior colliculus. In the
SC, total BDNF was significantly enhanced as soon as 6 h post-ONC, slowly decreasing to base-
line levels afterwards (Fig 10). Collicular TrkB-FL and TrkB-T1 levels followed a parallel
increase-decrease pattern after ONC. To date, the link between ONC and BDNF/TrkB expres-
sion in the retinal target areas has not yet been elucidated. However, since ONC directly
obstructs the retinal output, producing a quick drop in RGC-derived input into the visual brain
centers, the observed responses in the SC soon after ONC were not entirely unpredicted. Upre-
gulation of BDNF and TrkB in retinal target areas might in fact be an attempt to prevent post-
synaptic degeneration. Similarly, in the N-methyl-D-aspartate (NMDA) model, BDNF upregu-
lation in the dLGN and the SC has also been associated with RGC degeneration[65, 66].
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Fig 9. Literature overview on retinal BDNF and TrkB expression in murine optic nerve injury and OHTmodels. Key: BDNF, brain-derived
neurotrophic factor; mBDNF, mature form of BDNF; TrkB, tropomyosin receptor kinase B; TrkB-FL, TrkB full-length form; TrkB-T1, TrkB truncated form 1;
pTrkB, phosphorylated TrkB; ONC, optic nerve crush; LP, laser photocoagulation; OHT, ocular hypertension; ONH, optic nerve head; GCL, ganglion cell
layer; NLF, nerve fiber layer; ELISA, enzyme-linked immunosorbent assay; ISH, in situ hybridization; IHC, immunohistochemistry; RT-PCR; reverse
transcription polymerase chain reaction; hpi, hours post-injury; dpi, days post-injury.
doi:10.1371/journal.pone.0142067.g009
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In the OHTmodel, no significant effect on the BDNF concentration in the SC was measured
(Fig 10). In comparison, in DBA/2 mice, pre-degenerative transport deficits were found to be
accompanied by a decrement in BDNF mRNA expression in the retinorecipient SC, while con-
versely, mBDNF protein IHC signal increased, an observation that was confirmed in the
microbead-based OHT model[67]. The fact that no differences were measured in the collicular
BDNF levels within our study might be related to the model and the time points analyzed.
However, the additional possibility remains that a redistribution of BDNF occurs, changing its
Fig 10. Literature overview on collicular BDNF and TrkB expression in murine models of glaucoma. Key: BDNF, brain-derived neurotrophic factor;
mBDNF, mature form of BDNF; TrkB, tropomyosin receptor kinase B; TrkB-FL, TrkB full-length form; TrkB-T1, TrkB truncated form 1; ONC, optic nerve
crush; LP, laser photocoagulation; sSC, the superficial layers of the superior colliculus; NMDA, N-methyl-D-aspartate; ELISA, enzyme-linked immunosorbent
assay; ISH, in situ hybridization; IHC, immunohistochemistry; RT-PCR; reverse transcription polymerase chain reaction; hpi, hours post-injury; dpi, days
post-injury.
doi:10.1371/journal.pone.0142067.g010
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location and/or the pro-/mBDNF ratio without modifying the total concentrations. Neverthe-
less, our results did illustrate a slight reduction in TrkB-FL and TrkB-T1. Quite possibly, this
reduction stems from diminished anterograde TrkB delivery from the cell soma in the retina
towards the axon terminals in the SC or downregulation of TrkB expression by collicular cells.
Alternatively, the functional and structural degeneration of the RGC axon terminals might well
lead to reduced TrkB levels in the SC, since RGC synaptic terminals in the SC are affected as
soon as one week post-OHT induction[30].
Thus, BDNF-TrkB signaling is regulated by spatial and temporal changes in protein locali-
zation, gene expression, the mBDNF/pro-BDNF ratio, the TrkB-FL/TrkB-T1 ratio, and down-
stream signaling molecules. Defining a specific role for BDNF signaling within glaucoma
pathology remains difficult, as various studies, using a number of animal glaucoma models,
have culminated in a variety of unique results[63], the present work included.
Intravitreal delivery of BDNF delays glaucomatous RGC degeneration
while collicular BDNF upregulation does not
Based on the neurotrophin deprivation hypothesis, neurotrophins gained wide acceptance as
suitable candidates for neuroprotective drug usage. Indeed, upon experimentally induced glau-
coma, RGCs have been described to survive longer after ivt administration of various neuro-
trophic factors[9, 10, 68]. Amongst these, BDNF has been consistently shown as one of the
most powerful[7, 9, 69], though only delivering a transient neuroprotection[9, 45]. Our data
confirmed this temporary RGC protective effect of ivt delivery of recombinant BDNF in the
ONC model. The neuroprotective power of ivt BDNF may be caused by enhanced BDNF-TrkB
signaling in RGCs, resulting in the activation of pro-survival signaling pathways and the sup-
pression of apoptotic mechanisms[26, 70]. Yet, ivt BDNF might also affect RGC survival indi-
rectly via stimulation of Müller cells, to secrete other neuron supporting compounds[71].
Retinal TrkB levels were not downregulated upon ONC, as discussed above, and so ivt admin-
istered BDNF could indeed provide neuroprotection by promoting TrkB signaling in RGCs or
glia. However, the TrkB-FL/TrkB-T1 ratio shifted slightly towards the T1 isoform, of which the
exact role is not fully understood. Although initially defined as a dominant-negative receptor,
the truncated receptor also seems to fulfill other, possibly even survival promoting, functions
[22]. Therefore, it is hard to draw strong conclusions on how exactly ivt BDNF delivery pro-
motes RGC survival and why this effect is transient. Presumably, the latter is partly due to lim-
ited supply when administered ivt, but also to downregulation of the relevant receptors and
desensitization of the signal transduction pathways[7, 26, 72]. The decrease in responsiveness
to BDNF most likely stems from a downregulation in TrkB receptor availability, brought about
by decreased TrkB expression, internalization of the BDNF-bound receptors with reduced
replacement in the cell membrane, or competitive interactions with truncated TrkB receptors
[26]. Accordingly, combining ivt BDNF injections with transduction of RGCs with the TrkB
gene, notably enhanced the duration of ivt BDNF-induced neuroprotection after optic nerve
axotomy in rats[58].
Since local BDNF administration to the eye appears insufficient for sustained RGC survival,
we hypothesized that treatment at the level of extraretinal neurotrophin sources in the brain
might be favorable. Indeed, Weber et al. have demonstrated that combined application of
BDNF to the eye and the central visual pathway enhanced RGC survival and function relative
to treatment of the eye alone, in an ONC model in cats[7, 26]. Based on this finding, we
intended to deliver BDNF to the RGCs from a natural extraretinal source, the SC, in order to
induce RGC neuroprotection in murine glaucoma models. Unfortunately, although viral vec-
tor-mediated BDNF upregulation in the mouse SC was validated, the attempts to protect RGCs
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upon ONC or OHT through collicular vector treatment were unsuccessful. Nonetheless, vec-
tor-derived BDNF was shown to be secreted by transduced cells in vitro, and to be transformed
into the mature form in vivo. In addition, viral vector-derived BDNF was demonstrated to be
bio-active, since it stimulated neurite outgrowth in an ex vivo retinal explant culture. Notably,
as viral vector-based BDNF upregulation in the SC elicited effects on the availability of its
receptor (discussed in detail below), our findings clearly indicate that transgenically expressed
BDNF was secreted into the extracellular space by transduced collicular neurons in vivo as
well.
In line with our data, based on unpublished results showing that treatment of the visual cor-
tex alone was insufficient to provide RGC neuroprotection, Weber et al. postulated that the
enhanced survival achieved in their dual treatment paradigm was the result of the contribution
from both the eye and visual brain center treatment[7, 26]. They hypothesized that direct treat-
ment of the eye is necessary to sustain RGCs during the immediate post-injury period, in order
to counter the initial insult and short-term degenerative effects, whereas treatment of the brain
center provides more long-term stability. However, some additional issues need to be taken
into account. Indeed, more detailed investigation of responses to viral vector-mediated BDNF
overexpression revealed that upregulation of BDNF in the SC did not result in any enhance-
ment of BDNF levels in the retina. Thus, transgenically expressed BDNF did not seem to be ret-
rogradely transported by RGC axons. This was the case in both healthy conditions and after
ONC- or OHT-induced injury. Perhaps, if sufficient levels are available, RGCs do not alter
their normal transport rate. Of note, we cannot entirely exclude that some technical aspects
might have hampered the retrograde delivery of BDNF. Indeed, at the moment of ONC, axonal
transport is abruptly blocked in all RGC axons. Furthermore, although axonal damage has
been postulated to be rather indirectly in the OHT model[30, 31], the strong IOP elevation
seen in this study may possibly result in rather fast diminishment of the retrograde axonal
transport[64]. However, also in healthy conditions, viral-vector derived BDNF was not trans-
ported from the SC towards the retina. This observation is in contrast with previous studies,
demonstrating retrograde transport of collicular-injected tagged BDNF in rats, which is dimin-
ished and accompanied by accumulation of TrkB receptor in the ONH upon OHT induction
[64]. Of note, the more chronic feature of our setup, using viral vector based long-term overex-
pression of BDNF, in comparison to the acute delivery of tagged BDNF with sacrifice 4 h later,
might explain the different results. Indeed, our unfortunate finding might well be attributed to
the demonstrated downregulation of collicular TrkB-FL levels as a response to chronic BDNF
upregulation and secretion. Potentially, this downregulatory effect may be explained by a
reduction in the delivery of TrkB from the retina to the RGC axon terminals of the target area.
Assuming this downregulation of TrkB-FL is due to reduced availability of TrkB-FL on the
RGC axon terminals, the viral vector-derived BDNF will not be taken up at the RGC synapses
and thus will not be transported towards the retina. In keeping with the observation that colli-
cular TrkB-T1 levels did not change upon vector delivery, another possibility to explain the
lack of retrograde transport of vector-derived BDNF remains. Indeed, it is plausible that the
viral vector-derived BDNF is sequestered by glia in an effort to maintain extracellular BDNF
levels within normal ranges. In our opinion, downregulation of the TrkB-FL expression at the
RGC axon terminals seems the most reasonable explanation for the absence of retrograde
transport of the vector-derived BDNF. This is in agreement with previous findings in the ret-
ina, whereby downregulation of TrkB has been described upon ivt injection of recombinant
BDNF[7, 58, 72]. Thus, additional research should consider restoration of trophic responsive-
ness by increasing the number of TrkB-FL receptors present on the RGC terminals surface, e.g.
by overexpression[58, 73] or by enhancing their recruitment to the plasma membrane[74].
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Conclusion
The temporal course of RGC degeneration was characterized in two mouse models of experi-
mentally induced glaucoma, i.e. ONC and LP-induced OHT. Furthermore, endogenous BDNF
and TrkB expression patterns in the retina and SC were shown to be differentially affected
upon ONC or OHT induction. Using the ONCmodel, the neuroprotective capacity of ivt
BDNF administration was confirmed. Unfortunately, viral vector-induced overexpression of
BDNF in the SC did not result in enhanced RGC survival in none of the two glaucoma models.
These negative results seemed mainly attributed to reduced neurotrophin responsiveness as a
response to vector-mediated BDNF overexpression and secretion. Overall, our data provide
important information for the design of additional research on the neurotrophin-deprivation-
hypothesis in glaucoma.
Supporting Information
S1 Fig. Induced astroglial response, transduction efficiency, and retrograde transduction
capacity of different viral vectors upon delivery into the mouse SC. (A) Two weeks after
intracollicular delivery of different viral vectors (rAAV2/1, 2/7, 2/8, and 2/9), expressing the
eGFP gene under control of the general CMV promoter, astroglial reactivity, defined by upre-
gulated GFAP labeling, remains locally around the injection site (± 300 μm) for each vector
and the difference between rAAV vector-injected SC and sham controls is limited. Scale bars:
100 μm. (B) Unilateral transduction with rAAV2/1, rAAV2/7, rAAV2/8, and rAAV2/9, visual-
ized through CMV promoter-regulated eGFP expression, spreads throughout the entire SC in
anteroposterior and lateromedial direction. 200 μm spaced serial sections between Bregma
-3.30 mm and -4.50 mm are depicted. Scale bars: 200 μm. (C) In contrast to rAAV2/1, unilat-
eral injection of rAAV2/7, rAAV2/8, and rAAV2/9 vectors into the mouse SC results in retro-
grade transduction and eGFP expression in RGCs, identified through Brn3a IHC, in the eye
contralateral to the injected SC. Arrowheads point towards double-labeled cells, showing green
cytoplasm and a red nucleus. Scale bars: 20 μm. Key: GFAP, glial fibrillary acidic protein; IHC,
immunohistochemistry; SC, superior colliculus; RGC; retinal ganglion cell; eGFP, enhanced
green fluorescent protein; rAAV2/x, recombinant adeno-associated viral vector serotype 2/x;
CMV, cytomegalovirus promoter.
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